Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KMT2A | Q03164 | 2/20 | 0.39 |
| ▸ | FAAH | O00519 | 2/20 | 0.39 |
| ▸ | MEN1 | O00255 | 1/20 | 0.39 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.39 |
| ▸ | DNM1 | Q05193 | 1/20 | 0.39 |
| ▸ | CERT1 | Q9Y5P4 | 3/20 | 0.35 |
| ▸ | PLA2G10 | O15496 | 2/20 | 0.34 |
| ▸ | PLA2G2C | Q5R387 | 2/20 | 0.34 |
| ▸ | NOD1 | Q9Y239 | 2/20 | 0.34 |
| ▸ | CPT2 | P23786 | 1/20 | 0.34 |
| ▸ | CPT1A | P50416 | 1/20 | 0.34 |
| ▸ | CPT1B | Q92523 | 1/20 | 0.34 |
| ▸ | SMPD2 | O60906 | 1/20 | 0.34 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.33 |
| ▸ | ASAH1 | Q13510 | 1/20 | 0.33 |
| ▸ | ACER2 | Q5QJU3 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL24095986 | 0.84 | KMT2A (0.43) | KMT2AFAAHMEN1MAPK1DNM1 | |
| SCHEMBL24095940 | 0.79 | KMT2A (0.40) | KMT2AFAAHMEN1MAPK1DNM1 | |
| SCHEMBL25410296 | 0.76 | — | — | |
| SCHEMBL25410298 | 0.76 | — | — | |
| SCHEMBL24096062 | 0.72 | KMT2A (0.40) | KMT2AFAAHMEN1MAPK1DNM1 | |
| SCHEMBL24095971 | 0.72 | MEN1 (0.40) | KMT2AFAAHMEN1MAPK1DNM1 | |
| SCHEMBL24096157 | 0.72 | MEN1 (0.40) | KMT2AFAAHMEN1MAPK1DNM1 | |
| SCHEMBL24095910 | 0.70 | FAAH (0.47) | KMT2AFAAHDNM1 | |
| SCHEMBL24096074 | 0.70 | FAAH (0.42) | KMT2AFAAHMEN1MAPK1DNM1 | |
| SCHEMBL24096230 | 0.69 | FAAH (0.41) | KMT2AFAAHMEN1MAPK1DNM1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230234917-A1 | ASPARAGINE DERIVATIVES AND METHODS OF USING SAME | SENDA BIOSCIENCES INC (US) | 2023-07-27 | — | — | US | disclosed |
| US-20230234917-A1 | ASPARAGINE DERIVATIVES AND METHODS OF USING SAME | SENDA BIOSCIENCES INC (US) | 2023-07-27 | — | — | US | disclosed |
| WO-2021252640-A1 | ASPARAGINE DERIVATIVES AND METHODS OF USING SAME | SENDA BIOSCIENCES, INC. (US) | 2021-12-16 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230234917-A1 | ASPARAGINE DERIVATIVES AND METHODS OF USING SAME | ASNS, SI, NARS1 | KMT2A 4069/4885FAAH 3546/4885MEN1 433/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.